Protalix BioTherapeutics, Inc.

AMEX:PLX

Biotechnology

Healthcare
$3.02 +4.21%

+$0.09 today

Market cap
$254.64M
Beta
0.01
P/E (TTM)
11.0
EPS (TTM)
$0.19
52W Low $1.32High $3.19

Volume 0.96M

Average 0.81M

PLX EBITDA Margin

EBITDA as a percentage of revenue.

Protalix BioTherapeutics, Inc.AMEX: PLX

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to 64.4%

EBITDA Margin was 64.4% in Q1 FY2026, up 97.8 pp from a year earlier. On a trailing-twelve-month basis it was 29.2%, up 17.2 pp year over year. Over 3 fiscal years it widened by 17.0 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 1 analysts of 29.9% for the fiscal year ending Dec 2026, up from -5.6% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
64.4%+108.3 pp QoQ
Last fiscal yearDec 2025
-5.6%-17.8 pp YoY
LTMMar 2026
29.2%+17.2 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+97.8 pp-11.0 pp-108.9 pp
1 year-17.8 pp+35.5 pp+53.3 pp
3 years+17.0 pp+17.8 pp+0.8 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-5.6%
Year-over-year change
-17.8pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How PLX compares with its peers on the latest reported figures

  • PLX's LTM Mar 2026 EBITDA Margin of 29.2% is the highest of the 3 companies compared; the peer median is -32.3%.
  • Its year-over-year change of +17.2 pp is the highest of 3, against a peer median of +2.5 pp.
  • Over three fiscal years its change of +17.0 pp compares with a peer median of +49.0 pp.
PLX Competitors Peer median
EBITDA Margin for PLX and competitors
Company Period LTM level YoY 3-year change
PLXProtalix BioTherapeutics, Inc.LTM Mar 202629.2% +17.2 pp+17.0 pp
PHARPharming Group N.V.LTM Mar 202610.7% +3.9 pp-7.9 pp
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026-75.2% +1.0 pp+105.9 pp
PLYXPolaryx Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding PLX) -32.3%+2.5 pp+49.0 pp

Competitors are the stored peer set for PLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue38.35M47.64M65.49M53.4M52.74M
Cost of Revenue16.35M19.59M22.98M24.32M27.51M
Gross Profit22M28.05M42.51M29.08M25.24M
Gross Margin57.4%58.9%64.9%54.5%47.8%
Research & Development29.73M29.35M17.09M12.97M19.05M
Selling, General & Admin12.73M11.71M14.96M12.19M11.68M
Operating Expenses42.46M41.06M32.05M25.16M30.74M
Depreciation & Amortization1.12M1.09M1.19M1.3M1.47M
EBITDA(18.94M)(10.78M)12.94M6.52M(2.95M)
EBITDA Margin-49.4%-22.6%19.8%12.2%-5.6%
Operating Income(20.46M)(13.01M)10.46M3.92M(5.5M)
Operating Margin-53.4%-27.3%16.0%7.3%-10.4%
Interest Income401K1.15M1.29M1.3M1.08M
Interest Expense7.52M2.53M3.18M1.06M1.19M
Other Income / Expenses(7.12M)(1.38M)(1.89M)237K(108K)
Income Before Tax(27.58M)(14.4M)8.57M4.15M(5.61M)
Pre-Tax Margin-71.9%-30.2%13.1%7.8%-10.6%
Income Tax Expense0530K254K1.22M996K
Net Income(27.58M)(14.93M)8.31M2.93M(6.6M)
Net Margin-71.9%-31.3%12.7%5.5%-12.5%
EPS (Basic)(0.62)(0.31)0.120.04(0.08)
EPS (Diluted)(0.62)(0.31)0.100.04(0.08)
Weighted Avg Shares44.14M48.47M67.51M72.53M78.55M
Weighted Avg Shares (Diluted)44.14M48.47M82.42M81.06M78.55M

Protalix BioTherapeutics, Inc.

AMEX:PLX

Intrinsic Alpha fair value

Locked

Current Price

$3.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.